- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01001819
DNA Microarray Analysis of Gene Expression in Chronic Rhinosinusitis
April 3, 2018 updated by: Marvin Fried, Montefiore Medical Center
Analysis of differential gene expression in patients with chronic rhinosinusitis without polyps compared to unaffected patients.
Correlation of abnormal gene expression with surgical outcomes.
Study Overview
Status
Completed
Conditions
Study Type
Observational
Enrollment (Actual)
30
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
New York
-
Bronx, New York, United States, 10467
- Montefiore Medical Center
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Sampling Method
Non-Probability Sample
Study Population
Patients with Chronic Rhinosinusitis w/o nasal polyps who meet eligibilty requirements and are undergoing sinus surgery and patients w/o sinus disease who are undergoing intranasal surgery and meet eligbility requirements
Description
Affected patients:
Two or more of the following symptoms should be present for 12 weeks or more: anterior mucopurulent drainage, posterior mucopurulent drainage; nasal obstruction; and facial pain-pressure-fullness.
- Signs of nasal inflammation such as discolored mucus, edema of the middle meatus or ethmoid area should be documented by endoscopy.
- The symptoms of rhinosinusitis have failed to resolve or have recurred after a treatment course with antibiotics and nasal and/or oral steroids.
- The diagnosis of rhinosinusitis should be confirmed with a CT scan.
- Patients deny recent (within one year) cigarette smoking or exposure to inhaled substances that are potentially harmful to respiratory epithelium
- Patients were not previously diagnosed with reactive airway disease or aspirin sensitivity.
- Patients also must meet the standard criteria for endoscopic sinus surgery and scheduled to undergo their procedure at MMC.
Unaffected Patients:
Patients undergoing elective nasal surgery at MMC.
- Patients deny symptoms of allergic rhinitis such as nasal congestion, nasal discharge, itching, sneezing.
- Patients deny symptoms of chronic or acute rhinosinusitis such as nasal obstruction, facial pain-fullness-pressure, anosmia, anterior and/or posterior mucopurulent drainage.
- Nasal endoscopy showed no evidence of nasal inflammatory disease, such as erythema, edema, polyps, or discolored mucus.
Patients do not have history of prior sinus surgeries and were not previously diagnosed with CRS.
- Patients deny recent (within one year) cigarette smoking or exposure to inhaled substances that are potentially harmful to respiratory epithelium.
- Patients were not diagnosed with reactive airway disease or aspirin sensitivity.
- The absence of evidence of inflammation, such as inflammatory infiltrate or epithelial dysplasia on histopathologic exam of nasal mucosa obtained during surgical procedure.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
|---|
|
1
Chronic Rhinosinusitis w/o nasal polyps
|
|
2
No sinus disease
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Marvin P Fried, MD, Montefiore Medical Center/Albert Einstein College of Medicine
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
March 1, 2005
Primary Completion (Actual)
November 18, 2008
Study Completion (Actual)
November 18, 2008
Study Registration Dates
First Submitted
October 26, 2009
First Submitted That Met QC Criteria
October 26, 2009
First Posted (Estimate)
October 27, 2009
Study Record Updates
Last Update Posted (Actual)
April 5, 2018
Last Update Submitted That Met QC Criteria
April 3, 2018
Last Verified
April 1, 2018
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 05-01-005E
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Chronic Rhinosinusitis w/o Nasal Polyps
-
Region SkaneRecruitingChronic Rhinosinusitis With Nasal Polyps | Chronic Rhinosinusitis Without Nasal PolypsSweden
-
AstraZenecaRecruitingChronic Rhinosinusitis With Nasal PolypsChina
-
CSPC Baike (Shandong) Biopharmaceutical Co., Ltd.Not yet recruiting
-
AstraZenecaRecruitingChronic Rhinosinusitis With Nasal PolypsChina
-
SanofiRegeneron PharmaceuticalsNot yet recruiting
-
Rigshospitalet, DenmarkRecruitingChronic Rhinosinusitis With Nasal PolypsDenmark
-
SanofiRegeneron PharmaceuticalsEnrolling by invitationChronic Rhinosinusitis With Nasal PolypsUnited Kingdom, United States, Australia, China, Chile, South Korea, Canada
-
Polyganics BVNAMSANot yet recruitingChronic Rhinosinusitis (CRS) With and Without Nasal Polyps | Chronic Rhinosinusitis (CRS)
-
Tang-Du HospitalRecruitingEosinophilic Chronic Rhinosinusitis With Nasal PolypsChina
-
Longbio PharmaNot yet recruitingChronic Rhinosinusitis With Nasal Polyps (CRSwNP)China